Altimmune Inc
Sector: Manufacturing
Industry: Pharmaceutical Products
6.01
0.42
(7.51%)
Volume:
2,976,914
52 week range:
3.55 - 11.16
Market Cap:
462.852M
Company Description:
Altimmune, Inc. focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis.